Wedbush Downgrades Aimmune Therapeutics (AIMT) to Neutral
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Wedbush analyst Liana Moussatos downgraded Aimmune Therapeutics (NASDAQ: AIMT) from Outperform to Neutral with a price target of $34.50 (from $66.00).
For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.
Shares of Aimmune Therapeutics closed at $12.60 yesterday.
You May Also Be Interested In
- Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
- Seaport Global Securities Downgrades JetBlue Airways (JBLU) to Neutral
- EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
